Irinocan 40/Irinocan 100 Caution For Usage

Incompatibilities: This medicinal product must not be mixed with other medicinal products, except those mentioned in Dosage & Administration and Special precautions for disposal and other handling as follows.
Special precautions for disposal and other handling: As with other Antineoplastic agents, Irinotecan Injection must be prepared and handled with caution. Protective chamber should be used and protective gloves as well as protective gown should be worn. If there is no protective chamber available mouth cover and goggles should be used.
If Irinotecan solution or infusion solution should come into contact with the skin, wash immediately and thoroughly with soap and water. If Irinotecan solution or infusion solution should come into contact with the mucous membranes, wash immediately with water.
Preparation for the intravenous infusion administration: As with any other injectable drugs, the Irinotecan solution must be prepared aseptically. If any precipitate is observed in the vials or after dilution, the product should be discarded according to standard procedures for cytotoxic agents.
Aseptically withdraw the required amount of Irinotecan solution from the vial with a calibrated syringe and inject into a 250 mL infusion bag or bottle containing either 0.9% sodium chloride solution or 5% glucose solution. The infusion should then be thoroughly mixed by manual rotation.
Disposal: For single use only. All materials used for dilution and administration should be disposed of according to hospital standard procedures applicable to cytotoxic agents.